Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?

Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%? / Merola, E., Alonso Gordoa, T., Zhang, P., Al-Toubah, T., Pellè, E., Kolasińska-Ćwikła, A., Zandee, W., Laskaratos, F., de Mestier, L., Lamarca, A., Hernando, J., Cwikla, J., Strosberg, J., de Herder, W., Caplin, M., Cives, M., van Leeuwaarde, R.. - In: THE ONCOLOGIST. - ISSN 1083-7159. - 26:4(2021), pp. 294-301. [10.1002/onco.13633.]